Efficacy Study of Weekly Topotecan With Cisplatin in Advanced Stage or Recurrent Cervical Cancer
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of topotecan when
given weekly with cisplatin in patients with persistent, recurrent, or advanced stage
cervical cancer. Secondary purposes are to describe the toxicity profile in patients with
persistent, recurrent, or advanced stage cervical cancer treated with the combination of
topotecan when given weekly with cisplatin and to determine the response rate and time to
progression in patients with persistent, recurrent, or advanced stage cervical cancer treated
with the combination of topotecan when given weekly with cisplatin.